Baseline characteristics of three groups.

<p>HR: heart rate; MAP: mean arterial pressure; dp/dtmax: maximal rate of LV pressure increase; −dp/dtmax: maximal rate of LV pressure decline; EF: ejection fraction; FS: fractional shortening.</p><p>Values are means±SD.</p

Experimental protocol.

<p>Experimental protocol.</p

Representative Western blot images of SERCA2a, PLB and RyR 5(n = 6 for sham group; n = 10 for placebo or nitrite group) and 90 min (n = 6 for sham group; n = 10 for placebo or nitrite group) after ROSC are shown in A, C, E.

<p>The level of phosphorylated PLB was decreased significantly after resuscitation in the placebo group and nitrite administration preserved phosphorylated PLB during resuscitation. *<i>P</i><0.01 vs. sham group; †<i>P</i><0.05 vs. sham and placebo groups; ‡<i>P</i><0.05 vs. sham and nitrite groups.</p

Postresuscitation myocardial function evaluated by invasive monitoring and echocardiography (n = 6 for sham group; n = 10 for placebo or nitrite group).

<p><b>A</b>, The maximal rate of LV pressure increase (dp/dtmax) of each group, *<i>P</i><0.01 vs. sham and nitrite groups; †<i>P</i><0.05 vs. sham group. <b>B</b>, The maximal rate of LV pressure decline (−dp/dtmax) of each group, *<i>P</i><0.01 vs. sham group; †<i>P</i><0.05 vs. nitrite group; ^‡<i>P</i><0.01 vs. nitrite group. <b>C</b>, the ejection fraction of each group, *<i>P</i><0.01 vs. sham group; †<i>P</i><0.05 vs. sham group; ^‡<i>P</i><0.01 vs. nitrite group; <b>D</b>, the fractional shortening of each group; *<i>P</i><0.01 vs. sham and nitrite groups; †<i>P</i><0.05 vs. nitrite group.</p

CPR characteristics and basic hemodynamic parameters after ROSC.

<p>ROSC: return of spontaneous circulation; CPP: coronary perfusion pressure; CPR: cardiopulmonary resuscitation; HR: heart rate; MAP: mean arterial pressure; VF: ventricular fibrillation; VT: ventricular tachycardia.</p><p>Values are means±SD.</p

Color-Encoded Assays for the Simultaneous Quantification of Dual Cancer Biomarkers

For the first time, the scattering light of noble nanoparticles was applied for the simultaneous detection of dual cancer biomarkers. Two nanoprobes with dual scattering light colors were used for the simultaneous imaging of alpha-fetoprotein (AFP) and carcinoembryonic antigen (CEA) based on the sandwich-type immunoassay. Since AFP can combine anti-AFP-modified gold nanoparticles, which have green scattering light under the dark-field microscopic imaging (iDFM) technique, while CEA can conjugate anti-CEA-immobilized silver nanoparticles, which have blue scattering light, the simultaneous determination of AFP and CEA can be achieved by separately counting the number of green and blue light spots in iDFM. The mutual interference between the detection processes of AFP and CEA in the dual detection was investigated, and a negligible interference was found when the concentration of the antigen was in the range of 0.5–10 ng/mL, indicating the practicability of the simultaneous sensitive detection of dual targets. Furthermore, AFP and CEA in serum samples were also quantified directly without additional sample pretreatment, demonstrating the potential applications of the developed method in clinical diagnosis

Increasing expression of TRPV4 mRNA and protein during HSC activation.

<p>A. Total RNAs were isolated from TGF-β1-treated HSC-T6 cells, and subjected to qRT-PCR analyses. Representative images of three independent experiments are shown. *p<0.05 vs. non-treated cells. B. Whole-cell extracts were isolated from TGF-β1-treated HSC-T6 cells, and subjected to Western blot analyses with TRPV4 and β-actin antibodies. Representative blots of three independent experiments are shown. **p<0.01 vs. non-treated cells. C. Total RNAs were isolated from TGF-β1 treated HSC-T6 cells at different time points. The expression of α-SMA and Col1a1 mRNA was assessed by RT-PCR. Representative images of three independent experiments are shown. **p<0.01 vs. non-treated cells.</p

The RSVP paradigm used in this experiment.

<p>All words were in Chinese (containing pseudo-words and emotional nouns; see supplementary material for more details), and (A) each trial contained 12 pseudo-words (pw), two target stimuli (T1 and T2), and two questions (Q1 and Q2). The time interval between T1 and T2 was 234 ms. (B) Example for the two target stimuli in each trial. (C) Example for the two questions in each trail.</p

Blockade of TRPV4 inhibited the proliferation and decreased α-SMA expression in activated HSC-T6 cells.

<p>A. Total RNA extracts were made from HSC-T6 cells treated with or without TGF-β1 and Ru, and subjected to qRT-PCR analyses of TRPV4. Representative images of three independent experiments are shown. ^#p<0.05 vs. TGF-β1-treated cells. B. HSC-T6 cells were seeded in triplicate on day 0 and incubated in DMEM containing 10% fetal bovine serum or same media supplemented with Ru for further 24 h. Proliferation was measured by adding 5 mg/ml MTT reagent per well and incubating it for 4 h. ^#p<0.05 vs. TGF-β1-treated cells. C. Total RNA extracts were made from HSC-T6 cells treated with or without TGF-β1 and Ru, and subjected to qRT-PCR analyses of α-SMA. Representative images of three independent experiments are shown. ^#p<0.05 vs. TGF-β1-treated cells. D. Whole-cell protein extracts were made from HSC-T6 cells treated with or without TGF-β1 and Ru, and subjected to Western blot analyses of TRPV4. Representative images of three independent experiments are shown. ^##p<0.01 vs. TGF-β1-treated cells. E. HSC-T6 cells were treated with TGF-β1 for 48 h, followed by transfection with TRPV4-siRNA for an additional 48 h, and cell viability was determined by MTT assay. Mean±SE of two HSC preparations in quadruplets is shown; *p<0.05 vs. non-treated cells, ^#p<0.05 vs. TGF-β1-treated cells. F. Whole cell extracts were isolated from TGF-β1-treated HSC-T6 cells with RNAi transfection, and subjected to Western blot analyses. Representative images of three independent experiments are shown. **p<0.01 vs. non-treated cells, ^##p<0.01 vs. TGF-β1-treated cells.</p

Bone fracture before pMCAO increased behavioral deficits.

<p>(A) Adhesive removal test (right paw). Mice that received bone fracture took longer to remove adhesive from right paw. #: P<0.001 compared to stroke-only mice. *: P = 0.05: compared to stroke-only group. & = 0.02 compared to mice that received tibia fracture 24 hours before pMCAO. (B) Adhesive removal test (left paw). n = 10 for control groups (BF+3-day, BF+4day) that received tibia fracture and sham pMCAO, and had their behavioral test done 3 or 4 days after bone fracture. (C) Corner test. #: P = 0.001 compared to stroke group; *:P = 0.035 compared to stroke group. n = 10 for control groups (BF+3-day, BF+4day) that received tibia fracture and sham pMCAO, and had their behavioral test done 3 or 4 days after bone fracture. n = 10 for pMCAO-only group. n = 12 for groups that received bone fracture 6 hours or 24 hours before pMCAO. BF 6h Stroke: tibia fracture 6 hours before pMCAO; BF 24h stroke: tibia fracture 24 hours before pMCAO.</p